In a randomised, double-blind, active placebo-controlled trial of 24 fibromyalgia patients, a 30‑minute S‑ketamine infusion produced transient pain reductions that closely tracked plasma levels but yielded no significant long-term analgesic benefit over an eight‑week follow‑up versus midazolam. Side effects were mild–moderate and declined rapidly, suggesting adequate blinding.
- Published
- Journal
- European Journal of Pain
- Authors
- Aarts, L., Bauer, M., Dahan, A., Geleijnse, N., Mooren, R., Niesters, M., Noppers, I., Sarton, E., Swartjes, M.